Literature DB >> 23096177

Perfusion MDCT of prostate cancer: correlation of perfusion CT parameters and immunohistochemical markers of angiogenesis.

Marcello Osimani1, Davide Bellini, Claudio Di Cristofano, Giovanni Palleschi, Vincenzo Petrozza, Antonio Carbone, Andrea Laghi.   

Abstract

OBJECTIVE: The aim of our study was to correlate perfusion MDCT parameters and immunohistochemical markers of angiogenesis in prostate cancer. SUBJECTS AND METHODS: Twenty-two patients scheduled for radical surgical prostatectomy because of biopsy-proven prostate cancer underwent perfusion CT on a 64-MDCT scanner. Eight contiguous 5-mm sections were acquired at 1-second intervals for 45 seconds followed by three additional scans every 10 seconds after the administration of 80 mL of iodinated contrast medium (350 mg I/mL). Blood volume, blood flow, mean transit time, and permeability surface-area product were calculated, dividing each slice into nine square regions. Values obtained were correlated with the mean microvessel density (MVD) and mean vascular area of corresponding areas on histologic macrosections.
RESULTS: The mean values of the perfusion parameters detected on all square fields of patients with prostate cancer, benign hyperplasia, chronic prostatitis, and healthy tissue were, respectively, 18.36 ± 6.30, 19.49 ± 8.46, 19.67 ± 11.44, and 20.32 ± 4.53 mL/min/100 g for blood flow; 8.45 ± 2.75, 6.21 ± 4.32, 4.94 ± 2.31, and 5.44 ± 2.67 mL/100 mg for blood volume; 19.19 ± 4.45, 18.74 ± 4.91, 16.24 ± 4.12, and 16.37 ± 4.83 seconds for mean transit time; and 26.34 ± 11.88, 18.67 ± 9.15, 18.08 ± 7.72, and 19.93 ± 7.22 mL/min/100 g for permeability surface-area product. Both blood volume and the permeability surface-area product of cancerous squares showed the highest correlation with mean MVD and mean vascular area (0.618 [p < 0.01] and 0.614 [p < 0.01], respectively) and the highest area under the curve (0.769 and 0.708).
CONCLUSION: Our results show that blood volume and permeability surface-area product measurements obtained with perfusion CT have the highest correlation with immunohistochemical markers of angiogenesis in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23096177     DOI: 10.2214/AJR.11.8267

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  13 in total

1.  Assessment of prostate cancer with integrated CT-perfusion using a sector-wise approach.

Authors:  Matteo Ferrari; Martin Huellner; Chantal Pauli; Burkhardt Seifert; Hansjörg Danuser; Patrick Veit-Haibach; Agostino Mattei
Journal:  Turk J Urol       Date:  2017-05-03

2.  Feasibility study of CT perfusion imaging for prostate carcinoma.

Authors:  Nesat Cullu; Mecit Kantarci; Hayri Ogul; Senol Adanur; Aylin Okur; Erdem Koc; Berhan Pirimoglu; Leyla Karaca; Yesim Kizrak; Ozkan Polat
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

3.  CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.

Authors:  Avinash Kambadakone; Sam S Yoon; Tae-Min Kim; Daniel L Karl; Dan G Duda; Thomas F DeLaney; Dushyant V Sahani
Journal:  AJR Am J Roentgenol       Date:  2015-01       Impact factor: 3.959

Review 4.  The Continuing Evolution of Molecular Functional Imaging in Clinical Oncology: The Road to Precision Medicine and Radiogenomics (Part II).

Authors:  Tanvi Vaidya; Archi Agrawal; Shivani Mahajan; M H Thakur; Abhishek Mahajan
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

5.  Correlation between CT perfusion and clinico-pathological features in prostate cancer: a prospective study.

Authors:  Elżbieta Łuczyńska; Sylwia Heinze-Paluchowska; Paweł Blecharz; Barbara Jereczek-Fossa; Giuseppe Petralia; Massimo Bellomi; Andrzej Stelmach
Journal:  Med Sci Monit       Date:  2015-01-13

6.  Perfusion CT is a valuable diagnostic method for prostate cancer: a prospective study of 94 patients.

Authors:  Elzbieta Luczynska; Pawel Blecharz; Sonia Dyczek; Andrzej Stelmach; Giuseppe Petralia; Massimo Bellomi; Barbara Alicja Jereczek-Fossa; Jerzy Jakubowicz
Journal:  Ecancermedicalscience       Date:  2014-10-27

7.  Implementation of a phase detection algorithm for dynamic cardiac computed tomography analysis based on time dependent contrast agent distribution.

Authors:  Carsten Kendziorra; Henning Meyer; Marc Dewey
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

8.  A Bayesian Nonparametric Approach for Functional Data Classification with Application to Hepatic Tissue Characterization.

Authors:  Kassandra M Fronczyk; Michele Guindani; Brian P Hobbs; Chaan S Ng; Marina Vannucci
Journal:  Cancer Inform       Date:  2016-05-29

9.  Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy.

Authors:  Selina Tsim; Catherine A Humphreys; Gordon W Cowell; David B Stobo; Colin Noble; Rosemary Woodward; Caroline A Kelly; Laura Alexander; John E Foster; Craig Dick; Kevin G Blyth
Journal:  Lung Cancer       Date:  2018-02-03       Impact factor: 5.705

10.  Is angiogenesis a hallmark of prostate cancer?

Authors:  Gianluigi Taverna; Fabio Grizzi; Piergiuseppe Colombo; Pierpaolo Graziotti
Journal:  Front Oncol       Date:  2013-02-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.